Recently, SCN9A gene which encodes for NaV1.7 voltage-gated sodium channel, has been linked to molecular pathophysiologies of pain disorders like inherited erythromelalgia and inherited paroxysmal extreme pain disorder (PEPD) and has emerged as a therapeutic target for treatment of neuropathic pain [8] Additionally, nearly 20 disorders affecting skeletal muscle contraction, cardiac rhythm, or neuronal function have been linked to these mutations in human. The gene discussed is SCN9A; the disease is erythromelalgia.